



British Society for  
Paediatric Endocrinology  
and Diabetes

BSPED November 2021

**Save the Date!**



We are delighted to be able to release the new dates of the 48th Annual Meeting, which will take place from **Tuesday 2nd-Thursday 4th November 2022** at the ICC in Belfast. The BSPED Meeting, due to take place in Manchester, in 2022 will now take place in 2023 and the subsequent Meetings will similarly be pushed back. We would like to thank all of the future local convenors for their understanding about the impact the postponed Meeting has on the schedule

Thank you for your patience and understanding whilst we confirmed the new dates and began transferring the scientific programme and other arrangements. We believe moving the Annual Meeting to a virtual format was the best decision regarding the health, safety, and well-being of our delegates, speakers, exhibitors and other stakeholders and we very much look forward to coming together again next year.

**Keep an eye on the [website](#) for further details!**

## Benefactor Spotlight

The BSPED is very grateful for the support of our benefactors, without which the work of the Society would not be possible. We are pleased to introduce you to our 2021/2022 benefactors. Thank you to all of the following for their ongoing support:

### Partners:



**Merck** is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life, in biopharmaceuticals, developing therapies to treat cancer, multiple sclerosis, and endocrine conditions.

In endocrinology, Merck has established treatments in diabetes and growth hormone replacement, treating thousands of patients in the UK. With growth hormone therapy we are enhancing our digital tools in line with NHS Digital transformation plan and are committed to meeting patients' and healthcare professionals' evolving needs.

Merck has launched new systems and apps which work in conjunction or alongside the easypod™ injection device, to support both the patient and healthcare professional get the best from Merck therapies. New systems include: a new easypod™ Connect platform, growlink™ app and easypod™ Augment Reality (AR) App. These digital solutions are integrated to the MySupport patient support programme, available for device training and nurse-led support.



Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. For more information, visit [novonordisk.co.uk](https://www.novonordisk.co.uk), [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).



### **About Pfizer: Breakthroughs that change patients' lives**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

To learn more, please follow us on [Twitter](#), [Instagram](#) and like us on [Facebook](#).  
<https://www.pfizerpro.co.uk/>

### **Gold:**



Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialisation of life changing medicines.

As a leader in rare disease for more than 25 years, Alexion has developed and commercialised complement inhibitors to treat patients with complement-mediated disorders. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders. In addition, the company is developing several therapies and focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology



Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity.

You can learn more about the business of Kyowa Kirin at:  
<https://international.kyowa-kirin.com/uk/>

## Silver:



Diurnal Group plc is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions. Since inception in 2004, our company mission has been clear; to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients' quality of life.

Our expertise and innovative research activities focus on circadian-based endocrinology. We have created a specialised pipeline of product candidates within the endocrine area, with the primary goal of improving patient outcomes and lives.

**Diurnal – creating new therapies for patients with chronic hormone-related rare diseases**  
[www.diurnal.co.uk](http://www.diurnal.co.uk)

**Bronze:**



At Abbott, we believe people with diabetes should enjoy active lives, so we're focused on making breakthrough technology accessible and approachable for all. Our groundbreaking sensing technology is revolutionising how people monitor glucose and providing healthcare teams with more data to make better informed treatment decisions.

[www.FreeStyleDiabetes.co.uk](http://www.FreeStyleDiabetes.co.uk) and [www.FreeStyleLibre.co.uk](http://www.FreeStyleLibre.co.uk)



Insulet Corporation (NASDAQ: PDD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.

The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

For more information, please visit: [www.insulet.com](http://www.insulet.com) and [www.omnipod.com/en-gb/hcp](http://www.omnipod.com/en-gb/hcp)



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

For more information please visit [www.sanofi.co.uk](http://www.sanofi.co.uk).

## News from the BSPED Office

### Food for thought: BMJ link – continuity of care in diabetes

Last year's debate on continuity of care at the BSPED annual conference was a hot topic. Dr Rachel Besser, consultant paediatric endocrinologist from Oxford, has written about her experience in this BMJ post.

[Practicing medicine in the virtual world—continuity of care is even more important - The BMJ](#)

---

### Benefactor Resource Library

Head to the [BSPED Members' Area online](#) to find additional information, resources, promotional material and educational content from our benefactors in our Benefactor Resource Library.

All content is provided by our industry benefactors and any views expressed are not those of the BSPED.

More content is being added, so be sure to check back.

---



### BSPED Byelaws – for information

The byelaws (or rules) of the BSPED have recently been reviewed and slightly updated by the Executive Committee. This was mainly to reflect the updated membership categories and the fact that all BSPED members will be asked to renew their membership within three months of the due date each year rather than six, to ensure membership records are up to date. Honorary members are now voting members and we have also made provision for virtual AGMs, in circumstances such as those we have experienced over the past year.

[The current byelaws can always be found on the BSPED website.](#)

---

### Get all the latest endocrine news



Did you know that the BSPED website displays a regularly updated feed of endocrine and paediatric endocrine news from across the media? Visit the BSPED home page or our [dedicated news page](#) to stay up to date with new developments. News from the BSPED is also displayed.

# Trainee Update

## Diabetes & Endocrinology CSAC Meeting December 2021

The next CSAC meeting will take place in early December 2021. Please contact us with any queries or issues you would like us to raise with the CSAC. These can relate to SPIN Diabetes Training or GRID Endocrinology Training. Please email [bspedtrainerep@gmail.com](mailto:bspedtrainerep@gmail.com).

---

## PhD Opportunity at Queen Mary's University of London.

There is an exciting PhD Opportunity looking at 'Targeting adrenal stem cells by gene therapy to rescue adrenal insufficiency in Familial Glucocorticoid Deficiency' at Queen Mary's University of London. More information is available below:

<https://www.findaphd.com/phds/project/targeting-adrenal-stem-cells-by-gene-therapy-to-rescue-adrenal-insufficiency-in-familial-glucocorticoid-deficiency/?p136752>

---

## Virtual Paediatric Endocrine Teaching (VPET)

Dates for VPET have changed to the second Tuesday of every even month and second Friday of every odd month. The next session will be Tuesday 14<sup>th</sup> December 2021.

If you would like to be added to the VPET mailing list or would like further information, please email [vpet.trainees@gmail.com](mailto:vpet.trainees@gmail.com).

---

## Awards, Achievements and Appointments

We are keen to celebrate trainees' achievements in both endocrinology and diabetes. Please email [bspedtrainerep@gmail.com](mailto:bspedtrainerep@gmail.com) if there is anything you would like to share.

---

## BSPED Trainee Mailing List and Noticeboard

We send regular email updates on courses, job opportunities and information on training to trainees who are on our mailing list. Updates are also posted on our online noticeboard, which is hosted on Trello ([www.trello.com](http://www.trello.com)).

Please email [bspedtrainerep@gmail.com](mailto:bspedtrainerep@gmail.com) for further details of how to join or if you have feedback on any training issues.

---

Abiramy Fernando, Katherine Hawton & Rachel Boal  
BSPED/ RCPCH CSAC Trainee Representatives

## News from the Clinical Committee

### **SAFETY NOTICE- Fludrocortisone dosing National Neonatal Formulary 8th Edition**

<https://global.oup.com/academic/product/neonatal-formulary-9780198840787?cc=gb&lang=en&>

BSPED would like to make members aware of an error printed in the in the above National Neonatal Formulary 8<sup>th</sup> edition. The current edition states fludrocortisone doses in micrograms per kg rather than microgram per m<sup>2</sup>. This is being addressed by the publishers and the information is being shared with the neonatal networks and with the national phamacists network. It would be prudent for members to ensure staff in their units are aware of this and also highlight this error to referring shared care centres when fludrocortisone prescriptions are being advised.

---

### **Clinical Studies Group call for research narratives**

The CSG is aiming to showcase the breadth and depth of research in paediatric endocrinology and will host research narratives from each centre on the BSPED website. If you haven't done so already, you could write a paragraph or a page (or two) on current and future perspectives of research at your centre. Please contact the CSG Chair if you would like further information or if you would like to see an example. <https://www.bsped.org.uk/research/uk-research-perspectives/>



The BSPED Clinical Studies Group (CSG) is also aiming to refresh the list of studies on the website. If you have an exciting study in paediatric endocrinology and you'd like to share information about this, please contact the BSPED office. <https://www.bsped.org.uk/research/active-clinical-studies/>

---

### **BSPED statement on Covid-19 vaccination in children aged 12 - 15 with underlying health conditions**

The Joint Committee on Vaccinations and Immunisations (JCVI) has issued updated guidance on vaccination in children aged 12 to 15 years with underlying health conditions. **[Read more on this](#)** and find the **[full statement here](#)**.

---



## **BSPED Online Communication Strategy**

The clinical content of the website, newsletter and social media engagement falls under the remit of the Clinical Committee. A **BSPED Online Communication Strategy** has been formulated to increase engagement across the membership, provide a platform for guidance, advice and news and promote high quality training and professional development opportunities.



---

## **Declaration of interests for guideline endorsement**

If you would like a guideline to be endorsed or supported by the BSPED, we ask that you first complete a **declaration of interests form, which can be found here.**

---

## **\*Use of and comments regarding guidelines**

BSPED guidelines have been commissioned and endorsed by the BSPED and reflect the Society's views on best practice for the majority of patients with that condition. However, each patient should be considered as an individual in the context of their condition and other medication and therefore the readers' discretion is required in the application of their use. Every effort has been made to ensure the factual accuracy of the contents but no liability can be accepted for any litigation, claims or complaints arising from the use of the guidelines.

If you have a query or comment, or would like to raise a concern regarding a BSPED guideline or any guideline on our website, please contact the **BSPED Office** who will ensure your message is passed to the BSPED Clinical Guidelines Officer and Clinical Committee.

---

## **Surveys**

If you would like to include a survey in a BSPED newsletter to encourage responses from BSPED members, please submit it to the BSPED Office. The survey will be reviewed at the next Clinical Committee meeting and included in the newsletter if approved. Survey owners should agree to report their findings back to the Clinical Committee 6 months after the survey closes. The BSPED should be acknowledged in any output (guidelines, publications, presentations, etc) resulting from the survey and the BSPED Office informed of the output.



---

## **Submitting items to the Clinical Committee**

In order to manage the full agenda of this busy committee we would request that any items that members would like to be reviewed by the Clinical Committee should be submitted to the committee through the BSPED Office in good time. Please see below the deadline dates for submission for the upcoming Clinical Committee meeting: February 2022.

# Announcements

## Paediatric Endocrinology Clinical Research Fellowship posts Nuffield Department of Medicine, University of Oxford

Are you interested in doing clinical research? Do you want to become a leading paediatric diabetes academic of the future?

We are looking for dynamic, enthusiastic and committed paediatric trainees who would like to undertake a fellowship leading to a PhD, to work with us at the University of Oxford, in the area of type 1 diabetes screening. General population screening for childhood type 1 diabetes is an exciting new area of research both in the UK and internationally. Fellows will be supervised by Paediatric endocrinologist Dr Rachel Besser and Adult diabetologist/immunologist and type 1 diabetes consortium lead, Professor Colin Dayan. To understand more about this area, please follow this link for a recent review article we have published: <https://pubmed.ncbi.nlm.nih.gov/34740879/>



Successful candidates would be expected to register for a higher degree at the University of Oxford during the fellowship. Applicants must have GMC registration, and be on a paediatric training programme, and want to work in childhood type 1 diabetes.

The deadline for expressions of interest is December 31st 2021. For enquiries, please contact Dr Rachel Besser: [rachel.besser@ouh.nhs.uk](mailto:rachel.besser@ouh.nhs.uk)

---

## The Novo Nordisk UK Research Foundation 2022 Call for Applications

Applications are now invited for research and education funding in diabetes for 2022, all awards are made on a competitive basis. Applicants are preferred to be working in a patient facing role but this is not an absolute requirement. The Foundation is an independent registered charity: 1056410, AMRC member and a NIHR partner. Awards will be announced in April 2022.

**Research Fellowships** – this award is open to all healthcare professionals (e.g. doctors, nurses, podiatrists, dieticians...) working in diabetes and wishing to undertake a PhD: 3 years full-time, 4 years full-time with MSc year 1, or 5 years part-time.

**Grant Awards** – small research project grants in diabetes up to £12,000 open to all applicants.

### Closing date for Fellowship and Grant: 6 December 2021

**Fund Awards** – for nurses and allied healthcare professionals in diabetes care.

- Attendance at a national or international meeting (preference to those presenting their work) up to £1,000.
- A course of study up to £2,000.
- Clinical project up to £5,000.

### Closing date for the Fund Awards: 2 February 2022

---

## Competition Funded PhD Project (UK Students Only)

### Targeting adrenal stem cells by gene therapy to rescue adrenal insufficiency in Familial Glucocorticoid Deficiency

The Trustees of The Medical College of Saint Bartholomew's Hospital Trust (MCSBHT) have offered funding for a research studentship, for a clinically qualified candidate to commence in October 2022, leading to a PhD degree from The QMUL Faculty of Medicine and Dentistry.

This studentship will fund a student with a clinical qualification and GMC/GDC registration at any career stage below consultant. The Studentship will cover the successful candidate's current clinical salary and will include PhD fees (at home fee rate) with up to £6000 pa for consumables. Further consumables/funding for travel may be available on application.

Applications are encouraged ahead of interviews which will take place February 2022.  
[Click here](#) for further information.

---

## Locum Consultant Paediatric Endocrinologist 39 hours Children's Health Ireland at Crumlin

Children's Health Ireland (CHI) is leading on the clinical and operational transformation of acute paediatric healthcare and consists of hospitals at Crumlin, Temple Street and Tallaght. The three children's hospitals and CHI's Corporate Office transitioned from four separate, independently governed entities into one new single organisation effective from 1st January 2019 to govern and operate paediatric services in Dublin.

**For further information on how to apply for this role, [find the vacancy advert here](#).  
The closing date for applications is Tuesday, 30th November, 2022.**

---

You can get the latest articles published in ADC straight to your inbox by signing up the e alerts and TOC. Click below to sign up and stay up to date.

Archives of Disease in Childhood

- <https://emails.bmj.com/k/Bmj/jausu/archdischild>

Education & Practice edition

- <https://emails.bmj.com/k/Bmj/jausu/edpract>

Fetal & Neonatal edition

- <https://emails.bmj.com/k/Bmj/jausu/fetalneonatal>



# Meetings and courses

We have made every effort to check whether meetings have been postponed or cancelled due to Covid-19 and have updated the details below where possible. We would however recommend that you check with the website/organiser of any event you plan to attend this year.

---

## 2021-2022 Annual endocrinology and diabetes meetings

- [European Society of Endocrinology ECE 2022](#): 21-24 May 2022, Milan, Italy
  - [ENDO 2022](#): 11-14 June 2022, Atlanta, Georgia
- 

## Hypoglycaemia / Hyperinsulinism Study Day (Virtual)

by NORCHI (RMCH & AHCH) and GOSHCHI centres

Date: 8th December 2021 Time: 8.50 - 16.40

Please email Jacqueline Edwards (Jacqueline.Edwards@mft.nhs.uk) or Maria Estebanez (maria.salomonestebanez@mft.nhs.uk) for **free registration** or to find out more information.

---

## Hypoglycaemia / Hyperinsulinism Study Day (Virtual)

Organised by NORCHI (RMCH & AHCH) and GOSHCHI centres.

Date: 8th December 2021

Time: 8.50 - 16.40

To view the programme and register for the event please follow this link:

<https://www.eventbrite.co.uk/e/hypoglycaemia-hyperinsulinism-study-day-virtual-event-tickets-191589668857>

---

- **10th International Conference on Children's Bone Health**  
2-5 July 2022 in Dublin, Ireland  
<https://www.iccbh.org/>
  - **ICCBH Bone School**  
29 June – 1 July 2022 in Dublin, Ireland  
<https://www.iccbhboneschool.org/>
  - **14th International Conference on Osteogenesis Imperfecta**  
30 August to 2 September 2022 in Sheffield, UK  
<https://oi2022.org/>
-

## **Update in Obstetrics, Gynecology and Reproductive Medicine**

~~4-5 November 2021, Barcelona-Postponed until 2022~~

Unfortunately, at this time, COVID-19 still remains prominent in the public health sphere. Therefore, as the safety and well-being of all of the Dexeus Forum's participants, faculty and staff are our highest priority, we believe it is best to postpone the congress to a later date.

The Dexeus Women's Health Foundation has decided to postpone its 45th International Forum focusing on issues in Women's Health to 2022.

The face-to-face 2022 Dexeus Forum will follow in the footsteps of the previous highly successful Forums and will update the current knowledge in Obstetrics, Gynecology and Reproductive Medicine with the key international opinion leaders in each field.

<http://dexeus.comtecmed.com/>

---

## **16th ACDC Annual Conference 2022**

Next year's 2022 16<sup>th</sup> ACDC Annual Conference will be held at Conference Aston, Aston University Campus B74BL Birmingham on Friday, 4<sup>th</sup> February, 2022.

Please visit our website at <http://www.a-c-d-c.org/forthcoming-acdc-meetings/> to register to book your place via the Eventbrite link as tickets will be limited and on a first come first available basis-  
<https://www.eventbrite.co.uk/e/16th-acdc-annual-conference-tickets-162895798719>

---

See more Meetings and Courses on the [Other Meetings](#) page on the BSPED website.

If you have any meetings, courses or events that you'd like to add to this page, please [submit them for review here](#).

Sent by the BSPED Office  
BSPED  
c/o Bioscientifica Ltd  
Starling House,  
1600 Bristol Parkway North,  
Bristol, BS34 8YU  
[bsped@endocrinology.org](mailto:bsped@endocrinology.org)  
Tel: 01454 642258